303 related articles for article (PubMed ID: 30792264)
1. Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.
Janker L; Mayer RL; Bileck A; Kreutz D; Mader JC; Utpatel K; Heudobler D; Agis H; Gerner C; Slany A
Mol Cell Proteomics; 2019 May; 18(5):936-953. PubMed ID: 30792264
[TBL] [Abstract][Full Text] [Related]
2. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
3. Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.
Ravn Berg S; Dikic A; Sharma A; Hagen L; Vågbø CB; Zatula A; Misund K; Waage A; Slupphaug G
J Transl Med; 2024 Jun; 22(1):548. PubMed ID: 38849800
[TBL] [Abstract][Full Text] [Related]
4. High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
Fernandez N; Perumal D; Rahman A; Kim-Schulze S; Yesil J; Auclair D; Adams H; Parekh S; Gnjatic S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):853-862. PubMed ID: 35945129
[TBL] [Abstract][Full Text] [Related]
5. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
6. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
7. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
9. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
10. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.
Bae J; Accardi F; Hideshima T; Tai YT; Prabhala R; Shambley A; Wen K; Rowell S; Richardson PG; Munshi NC; Anderson KC
Leukemia; 2022 Jan; 36(1):138-154. PubMed ID: 34290359
[TBL] [Abstract][Full Text] [Related]
11. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Mussetti A; Pellegrinelli A; Cieri N; Garzone G; Dominoni F; Cabras A; Montefusco V
Ann Hematol; 2019 Jul; 98(7):1713-1720. PubMed ID: 31053880
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
14. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
15. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma.
Chhabra S; Jain S; Wallace C; Hong F; Liu B
J Hematol Oncol; 2015 Jun; 8():77. PubMed ID: 26108343
[TBL] [Abstract][Full Text] [Related]
16. MGUS to myeloma: a mysterious gammopathy of underexplored significance.
Dhodapkar MV
Blood; 2016 Dec; 128(23):2599-2606. PubMed ID: 27737890
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
[TBL] [Abstract][Full Text] [Related]
18. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
[TBL] [Abstract][Full Text] [Related]
19. An atlas of the bone marrow bone proteome in patients with dysproteinemias.
Ho M; Dasari S; Visram A; Drake MT; Charlesworth MC; Johnson KL; Pujari GP; Jevremovic D; Kourelis T
Blood Cancer J; 2023 Apr; 13(1):63. PubMed ID: 37105956
[TBL] [Abstract][Full Text] [Related]
20. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
